173 related articles for article (PubMed ID: 37358619)
1. Prognostic value of imaging-based ATN profiles in a memory clinic cohort.
Peretti DE; Ribaldi F; Scheffler M; Chicherio C; Frisoni GB; Garibotto V
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3313-3323. PubMed ID: 37358619
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease.
Delmotte K; Schaeverbeke J; Poesen K; Vandenberghe R
Alzheimers Res Ther; 2021 Apr; 13(1):84. PubMed ID: 33879243
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal change in ATN biomarkers in cognitively normal individuals.
Ebenau JL; Visser D; Kroeze LA; van Leeuwenstijn MSSA; van Harten AC; Windhorst AD; Golla SVS; Boellaard R; Scheltens P; Barkhof F; van Berckel BNM; van der Flier WM
Alzheimers Res Ther; 2022 Sep; 14(1):124. PubMed ID: 36057616
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline.
Bucci M; Chiotis K; Nordberg A;
Mol Psychiatry; 2021 Oct; 26(10):5888-5898. PubMed ID: 34593971
[TBL] [Abstract][Full Text] [Related]
6. Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies.
van de Beek M; Ooms FAH; Ebenau JL; Barkhof F; Scheltens P; Teunissen CE; van Harten AC; van der Flier WM; Lemstra AW
Neurology; 2022 Mar; 98(12):e1262-e1272. PubMed ID: 35074893
[TBL] [Abstract][Full Text] [Related]
7. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.
Ebenau JL; Timmers T; Wesselman LMP; Verberk IMW; Verfaillie SCJ; Slot RER; van Harten AC; Teunissen CE; Barkhof F; van den Bosch KA; van Leeuwenstijn M; Tomassen J; Braber AD; Visser PJ; Prins ND; Sikkes SAM; Scheltens P; van Berckel BNM; van der Flier WM
Neurology; 2020 Jul; 95(1):e46-e58. PubMed ID: 32522798
[TBL] [Abstract][Full Text] [Related]
8. Exploring the ATN classification system using brain morphology.
Heinzinger N; Maass A; Berron D; Yakupov R; Peters O; Fiebach J; Villringer K; Preis L; Priller J; Spruth EJ; Altenstein S; Schneider A; Fliessbach K; Wiltfang J; Bartels C; Jessen F; Maier F; Glanz W; Buerger K; Janowitz D; Perneczky R; Rauchmann BS; Teipel S; Killimann I; Göerß D; Laske C; Munk MH; Spottke A; Roy N; Heneka MT; Brosseron F; Dobisch L; Ewers M; Dechent P; Haynes JD; Scheffler K; Wolfsgruber S; Kleineidam L; Schmid M; Berger M; Düzel E; Ziegler G;
Alzheimers Res Ther; 2023 Mar; 15(1):50. PubMed ID: 36915139
[TBL] [Abstract][Full Text] [Related]
9. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.
Jack CR; Wiste HJ; Therneau TM; Weigand SD; Knopman DS; Mielke MM; Lowe VJ; Vemuri P; Machulda MM; Schwarz CG; Gunter JL; Senjem ML; Graff-Radford J; Jones DT; Roberts RO; Rocca WA; Petersen RC
JAMA; 2019 Jun; 321(23):2316-2325. PubMed ID: 31211344
[TBL] [Abstract][Full Text] [Related]
10. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
11. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
12. Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders.
Régy M; Dugravot A; Sabia S; Bouaziz-Amar E; Paquet C; Hanseeuw B; Singh-Manoux A; Dumurgier J
Alzheimers Res Ther; 2023 Apr; 15(1):77. PubMed ID: 37038213
[TBL] [Abstract][Full Text] [Related]
13. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease diagnostic accuracy by fluid and neuroimaging ATN framework.
Xiong X; He H; Ye Q; Qian S; Zhou S; Feng F; Fang EF; Xie C
CNS Neurosci Ther; 2024 Feb; 30(2):e14357. PubMed ID: 37438991
[TBL] [Abstract][Full Text] [Related]
15. Baseline [
Teng E; Manser PT; Sanabria Bohorquez S; Wildsmith KR; Pickthorn K; Baker SL; Ward M; Kerchner GA; Weimer RM
Alzheimers Res Ther; 2021 Dec; 13(1):196. PubMed ID: 34852837
[TBL] [Abstract][Full Text] [Related]
16. Applying the ATN scheme in a memory clinic population: The ABIDE project.
Altomare D; de Wilde A; Ossenkoppele R; Pelkmans W; Bouwman F; Groot C; van Maurik I; Zwan M; Yaqub M; Barkhof F; van Berckel BN; Teunissen CE; Frisoni GB; Scheltens P; van der Flier WM
Neurology; 2019 Oct; 93(17):e1635-e1646. PubMed ID: 31597710
[TBL] [Abstract][Full Text] [Related]
17. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
18. AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome.
Hartley SL; Handen B; Tudorascu D; Lee L; Cohen A; Schworer EK; Peven JC; Zammit M; Klunk W; Laymon C; Minhas D; Luo W; Zaman S; Ances B; Preboske G; Christian BT;
Alzheimers Dement; 2024 Jan; 20(1):366-375. PubMed ID: 37641428
[TBL] [Abstract][Full Text] [Related]
19. Distinct amyloid and tau PET signatures are associated with diverging clinical and imaging trajectories in patients with amnestic syndrome of the hippocampal type.
Lagarde J; Olivieri P; Tonietto M; Gervais P; Comtat C; Caillé F; Bottlaender M; Sarazin M
Transl Psychiatry; 2021 Sep; 11(1):498. PubMed ID: 34588422
[TBL] [Abstract][Full Text] [Related]
20. Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort.
Canu E; Rugarli G; Coraglia F; Basaia S; Cecchetti G; Calloni SF; Vezzulli PQ; Spinelli EG; Santangelo R; Caso F; Falini A; Magnani G; Filippi M; Agosta F
J Neurol; 2024 May; 271(5):2716-2729. PubMed ID: 38381175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
